secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amneal Pharmaceuticals, Inc. (AMRX)
CIK:        0001723128
Form:       8-K12B
Filed at:   2023-11-08T23:59:59+00:00
Accession:  0001193125-23-272933
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 3.01, 5.03, 8.01, 3.02, 3.03, 5.01, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amneal completes UP-C elimination, new holding company becomes public issuer
----------------------------------------------------------------------------

- Old Amneal became wholly-owned subsidiary of New Amneal; New Amneal renamed to Amneal Pharmaceuticals, Inc. and continues trading under AMRX.
- Tax Receivable Agreement amended: Amneal Group's share of tax savings reduced from 85% to 75%.
- Amneal OpCo's Fourth Amended LLC Agreement removes requirement for tax distributions to former members.
- Directors and executive officers remain identical; shares continue trading on NYSE with same CUSIP.
- 152,116,890 shares of New Amneal Class A common stock issued in conversion of common units.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1723128/000119312523272933/0001193125-23-272933-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1723128/000119312523272933/d454203d8k12b.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-272933

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer